Coagulation: International Normalized Ratio (INR) < . times normal, activated Partial Thromboplastin Time (aPTT) < . times normal. Patients receiving therapeutic doses of anticoagulant therapy may be considered eligible for the trial if INR and aPTT are within the acceptable therapeutic limits for the institution.
Prothrombin time, international normalized ratio (INR), and/or activated partial thromboplastin time within =< . x ULN (for treatment phase)
Any of the following abnormal laboratory values (unless due to underlying lymphoma): International normalized ratio (INR) or prothrombin time (PT) >.*upper limit of normal (ULN) in the absence of therapeutic anticoagulation; partial thromboplastin time (PTT) or activated partial thromboplastin time (aPTT) >.*ULN in the absence of a lupus anticoagulant
Patients must have adequate coagulation function as evidenced by prothrombin time (PT), activated partial thromboplastin time (aPTT) and international normalized ratio (INR) within normal institutional limits
Has adequate blood clotting function, defined as: International normalized ratio (INR) and activated partial thromboplastin time (aPTT) =< . x ULN.
Prothrombin time (PT) such that the international normalized ratio (INR) is < . x ULN and activated partial thromboplastin time (aPTT) < . x ULN; prophylactic heparin or low molecular weight heparin (enoxaparin or alternative anticoagulants [other than warfarin]) are acceptable
Obtained within  days prior to registration: International normalized ratio (INR) or prothrombin time (PT) activated partial thromboplastin time (aPTT) =< .
For patients with planned deep tumor injections: prothrombin time (PT), activated partial thromboplastin time (aPPT), and international normalized ratio (INR) within normal limits; Platelet count ?,/?L; hemoglobin ?  gm/dL.
For participants not receiving therapeutic anticoagulation: International normalized ratio (INR) or activated partial thromboplastin time (aPTT) less than or equal to (</=) .*upper limit of normal (ULN) within  days prior to initiation of study treatment
Prothrombin time/International Normalized Ratio (PT/INR) < . x ULN and partial thromboplastin time (PTT) activated partial thromboplastin time (aPTT) < . x ULN
International normalized ratio (INR) ?. or prothrombin time (PT) ?.  ULN; and either partial thromboplastin time or activated partial thromboplastin time (PTT or aPTT) ?.  ULN.
International normalized ratio (INR) and activated partial thromboplastin time (aPTT) < . x ULN (for patients on anticoagulation they must be receiving a stable dose for at least  week prior to enrollment)
Prothrombin time (PT/international normalized ratio [INR]) and activated partial thromboplastin time (aPTT) must be within  to % of the normal range at baseline
International normalization ratio (INR) and activated partial thromboplastin time (aPTT) < . x ULN
Within  days prior to administration of study treatment: Coagulation parameters (international normalized ratio [INR] and activated partial thromboplastin time [aPTT]) within . x ULN institutional limits, except where a lupus anti-coagulant has been confirmed, or except patients on anticoagulation
Prothrombin time (PT) and/or prothrombin time international normalized ratio (PT-INR) and/or activated partial thromboplastin time (APTT) =< . x ULN
Institutional normalized ratio (INR) and partial thromboplastin time (aPTT) < . x ULN
Institutional normalized ratio (INR) and partial thromboplastin time (aPTT) =< . x ULN
International normalized ratio (INR) and activated partial thromboplastin time (aPTT) =< . x ULN for patients who do not receive therapeutic anticoagulation
Prothrombin time (PT)/international normalized ratio (INR) < . x ULN and activated partial thromboplastin time (aPTT) < . x ULN (unless abnormalities are unrelated to coagulopathy or bleeding disorder)
Performed within  days of treatment initiation: International normalized ratio (INR) or prothrombin time (PT)\r\nactivated partial thromboplastin time (aPTT) =< . X ULN; if on active anticoagulants prior to study treatment, levels must be within standard therapeutic ranges per investigator
International normalized ratio (INR) and activated partial thromboplastin time (aPTT) =< . x ULN within  days prior to study enrollment
Within  days of the first study treatment: International normalized ratio (INR) and activated partial thromboplastin time (aPTT) =< . x ULN (for patients on anticoagulation they must be receiving a stable dose for at least  week prior to randomization)
International normalized ratio (INR)/prothrombin time (PT), activated partial thromboplastin time (aPTT) =< . x ULN unless on therapeutic warfarin then INR/PT =< . obtained =<  days prior to registration
International normalized ratio (INR) and activated partial thromboplastin time (aPTT) =< . x ULN; unless the patient is on therapeutic anticoagulation in which case the INR and aPTT must be within the therapeutic range of intended use of anti-coagulants
Prothrombin time (PT) and activated partial thromboplastin time (aPTT) levels ?. x ULN. If institution does not report PT value, the international normalization ratio (INR) must be ? ULN.
International normalized ratio (INR), prothrombin time (PT), or activated partial thromboplastin time (APTT) as follows: \r\n* In the absence of therapeutic intent to anticoagulate the patient: INR < . or PT < . x ULN or aPTT < . x ULN\r\n* In the presence of therapeutic intent to anticoagulate the patient: INR or PT and aPTT within therapeutic limits (according to the medical standard in the institution) and the patient has been on a stable dose of anticoagulants for at least  weeks before registration
Obtained =<  days prior to registration: International normalized ratio (INR)/prothrombin time (PT) and activated partial thromboplastin time (aPTT) =< . x ULN
Acceptable coagulation status: international normalised ratio (INR) of blood clotting, prothrombin time and activated partial thromboplastin time within ?. x upper limit of normal (ULN).
Prothrombin time (PT)/international normalized ratio (INR) =< . x ULN and partial thromboplastin time (PTT) (activated partial thromboplastin time [aPTT]) =< . x ULN (unless B-ALL related)
Normal prothrombin time (PT) or international normalized ratio (INR) and normal activated partial thromboplastin time (aPTT)
Prothrombin time (PT)/international normalized ratio (INR) < . x ULN and partial thromboplastin time (PTT) (activated partial thromboplastin time [aPTT]) < . x ULN
Impaired coagulation as evidenced by:\r\n* International normalized ratio (INR) > . times ULN, or\r\n* Activated partial thromboplastin time (aPTT) > . times ULN
Adequate hemostatic function as determined by prothrombin time (PT), international normalized ratio (INR) and activated partial thromboplastin time (aPTT) < . x ULN (unless on therapeutic coagulation, in which case the adequate level of anticoagulation will be determined by the investigator)
Prothrombin time (PT)/international normalized ratio (INR) < . x ULN and partial thromboplastin time (PTT) (activated partial thromboplastin time [aPTT]) < . x ULN
Within  days prior to registration: International normalized ratio (INR), prothrombin time (PT), or activated partial thromboplastin time (aPTT) as follows:\r\n* In the absence of therapeutic intent to anticoagulate the patient: INR < . or PT < . x upper normal limit (ULN) or aPTT < . x ULN\r\n* In the presence of therapeutic intent to anticoagulate the patient: INR or PT and aPTT within therapeutic limits (according to the medical standard in the institution) and the patient has been on a stable dose of anticoagulants for at least  weeks before registration
UROTHELIAL CARCINOMA EXPANSION COHORT: Prothrombin (PT)/international normalized ratio (INR) and activated partial thromboplastin time (aPTT) within . X ULN institutional limits, except where a lupus anti-coagulant has been confirmed
International normalized ratio (INR) =< . or prothrombin time (PT) =< . ULN, and a partial thromboplastin time (PTT/activated partial thromboplastin time [aPTT]) =< . x ULN
International normalized ratio (INR) or prothrombin time (PT) activated partial thromboplastin time (aPTT) =< . X ULN; patients on anticoagulation are expected to hold anticoagulation for at least  days prior to surgery
Performed within  days (+ working days) of treatment initiation: Coagulation international normalized ratio (INR) or prothrombin time (PT), activated partial thromboplastin time (aPTT) =< . X ULN
Normal coagulation parameters (elevated international normalized ratio (INR), prothrombin time or activated partial thromboplastin time (APTT) ?. ULN range acceptable).
Subjects must have adequate blood clotting function, defined as international normalized ratio (INR) and activated partial thromboplastin time (aPTT) =< . x ULN
International Normalized Ratio (INR) > . ULN or activated partial thromboplastin time (aPTT) > . ULN. Subject is currently receiving or intending to receive anti-coagulants for therapeutic purposes. Prophylactic use of anticoagulants is allowed.
Prothrombin time (PT) (or international normalized ratio [INR]) and partial thromboplastin time (PTT) (or activated partial thromboplastin time [aPTT]) > . x ULN
International normalized ratio (INR) and activated partial thromboplastin time (aPTT) =< . x ULN (for patients on anticoagulation they must be receiving a stable dose for at least  week prior to randomization)
Has adequate blood clotting function, defined as: - International normalized ratio and activated partial thromboplastin time =<. XULN
Requirement for anticoagulation treatment that increases international normalized ratio (INR) or activated partial thromboplastin time (aPTT) above the normal range (low dose deep vein thrombosis (DVT) or line prophylaxis is allowed).
Prothrombin time (PT)/international normalized ratio (INR)/ activated partial thromboplastin time (aPTT) =< . x ULN (to be performed within  days prior to start of study treatment)
International normalized ratio =< . and activated prothrombin time =< . x ULN within  days prior to enrollment; the use of full-dose oral or parenteral anticoagulants is permitted as long as the international normalized ratio (INR) or activated partial thromboplastin time (aPTT) is within therapeutic limits (according to the medical standard of the enrolling institution) and the patient has been on a stable dose of anticoagulants for at least two weeks prior to the first study treatment
Patients must have adequate coagulation (international normalized ratio [INR] ? ., activated partial thromboplastin time [aPTT] ?. X the upper limit of normal [ULN])
All screening labs should be performed within  days (+ working days) of treatment initiation: international normalized ratio (INR) or prothrombin time (PT), activated partial thromboplastin time (aPTT) =< . x ULN.
International normalized ratio (INR) within . times ULN (or if receiving anticoagulant therapy an INR of =< . is allowed with concomitant increase in prothrombin time (PT) or an activated partial thromboplastin time (aPTT) =< . x control)
Prothrombin time (PT) or international normalized ratio (INR) and activated partial thromboplastin time (aPTT) < . times upper limit of normal
International normalized ratio (INR) and activated partial thromboplastin time (aPTT) =< . x ULN
Prothrombin time (PT)/international normalized ratio (INR) and activated partial thromboplastin time (aPTT) must be < . x the upper limit of the normal range (ULN); except if, in the opinion of the investigator, the aPTT is elevated because of a positive lupus anticoagulant
International normalized ratio (INR) =< . and activated partial thromboplastin time (aPTT) within . x ULN; patients on warfarin therapy are not eligible due to the requirement for multiple biopsies
International normalized ratio (INR), activated partial thromboplastin (aPTT), or partial thromboplastin time (PTT) < .  ULN (unless on anticoagulant treatment at screening)
Baseline laboratory data as defined as: Hemoglobin (Hb): >=g/dL Absolute Neutrophil Count (ANC): >=/L Platelet (PLT): >=/L Glomerular Filtration Rate (GFR) or Creatinine Clearance: >=ml/min Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT): < x Upper Limit of Normal (ULN) Bilirubin - total: <. x ULN Activated Partial Thromboplastin Time (aPTT), Prothrombin Time (PT) or International Normalized Ratio (INR): <=. x ULN PT <=. x ULN, INR <=.
Prothrombin time (PT)/international normalized ratio (INR) =< . x ULN and partial thromboplastin time (PTT) (activated partial thromboplastin time [aPTT]) < . x ULN
For patients not receiving therapeutic anticoagulation: international normalized ratio (INR) or activated partial thromboplastin time (aPTT) =< . x ULN, obtained within  days prior to initiation of study treatment
Individuals not receiving anticoagulant medication must have an international normalized ratio (INR) ? . and activated partial thromboplastin (aPTT) ? . x upper limit of normal (ULN)
Prothrombin time (PT)/international normalized ratio (INR) < . x ULN and partial thromboplastin time (PTT) (activated partial thromboplastin time [aPTT]) < . x ULN
International normalized ratio (INR) and activated partial thromboplastin time (aPTT) > . x ULN, in subject who is not therapeutically anticoagulated.
International normalized ratio (INR) and activated partial thromboplastin time (aPTT) =< . X ULN unless on medication known to alter INR and/or aPTT
International normalized ratio (INR) ? . and activated partial thromboplastin time (aPTT) ? . x the ULN.
Prothrombin time (PT)/ international normalized ratio (INR)/activated partial thromboplastin time (aPTT) =< . x institutional upper limit of normal
Within  days prior to registration: coagulation parameters (international normalized ratio [INR], activated partial thromboplastin time [aPTT]) =< . x institutional ULN
Prothrombin time (PT)/international normalized ratio (INR)/partial thromboplastin time (PTT) (activated partial thromboplastin time [aPTT]) < . x institutional upper limit of normal, within  days of study registration
International normalized ratio (INR), prothrombin time (PT), or activated partial thromboplastin time (APTT) as follows: in the absence of therapeutic intent to anticoagulate the patient: INR < . or PT < . x ULN or aPTT < . x ULN; in the presence of therapeutic intent to anticoagulate the patient: INR or PT and aPTT within therapeutic limits (according to the medical standard in the institution) and the patient has been on a stable dose of anticoagulants for at least  weeks before registration (within  days prior to registration)
Coagulation parameters (international normalized ratio [INR], activated partial thromboplastin time [aPTT]) =< . x ULN institutional limits, except where a lupus anti-coagulant has been confirmed
International normalized ratio (INR) or prothrombin time (PT) activated partial thromboplastin time (aPTT) =< . X ULN; if on active anticoagulants prior to study treatment, levels must be within standard therapeutic ranges per investigator
Adequate coagulation parameters, defined as International Normalisation Ratio <. x ULN or activated partial thromboplastin time <. x ULN.
Prothrombin time (PT)/international normalized ratio (INR) < . ULN and partial thromboplastin time (PTT) activated partial thromboplastin time (aPTT) < . X ULN; if value is higher due to hepatic involvement by CLL, patient is eligible
At least  weeks ( days) prior to registration: Prothrombin time (PT)/international normalized ratio (INR) and activated partial thromboplastin time (aPTT) =< . x ULN (unless on medication known to alter INR and aPTT)
International normalized ratio (INR), activated partial thromboplastin time (aPTT) or partial thromboplastin time (PTT) > .  ULN (unless on anticoagulation medication)
Prothrombin time (PT)/international normalized ratio (INR) < . x ULN and partial thromboplastin time (PTT)/activated partial thromboplastin time (aPTT) < . x ULN
International normalized ratio (INR) =< . and activated partial thromboplastin time (aPTT) within normal limits (WNL)
Prothrombin time (PT) or international normalized ratio (INR), and activated partial thromboplastin time (APTT) =< . x upper limit of normal (ULN), unless the abnormality can be explained by the presence of lupus anticoagulant or if these values are in the therapeutic range for a patient on low molecular weight heparin
International normalized ratio (INR) > . and activated partial thromboplastin time (aPTT) > . x the ULN (except for subjects receiving anticoagulation therapy) in the absence of therapeutic intent to anticoagulate the subject; therapeutic anticoagulation is permitted
International normalized ratio (INR) and activated partial thromboplastin time (aPTT) =< . X ULN unless on medication known to alter INR and aPTT
Prothrombin time (PT)/international normalized ratio (INR) > . x ULN and partial thromboplastin time (PTT) (activated partial thromboplastin time [aPTT]) > . x ULN (unless abnormalities are unrelated to coagulopathy or bleeding disorder)
Coagulation parameters (international normalized ratio [INR], activated partial thromboplastin time [aPTT]) within . x upper limit of normal institutional limits, except where a Lupus anti-coagulant has been confirmed
International normalized ratio (INR), activated partial thromboplastin time (aPTT), or partial thromboplastin time (PTT) < .  ULN (unless on anticoagulant treatment at screening)
International normalized ratio (INR) and activated partial thromboplastin time (aPTT) =< . x ULN\r\n* Unless the patient is on therapeutic anticoagulation
Serum creatinine >ULN, or Prothrombin time (PT) or international normalized ratio (INR) >.  ULN or activated partial thromboplastin time (aPTT) > .  ULN
Activated partial thromboplastin time (aPTT) ? . ULN and international normalized ratio (INR) ? . (unless the subject is receiving therapeutic anticoagulants);
Has adequate blood clotting function, defined as: International normalized ratio and activated partial thromboplastin time <= . X ULN
International normalized ratio (INR) and activated partial thromboplastin time (aPTT) </=  x ULN
International normalized ratio (INR) > . and activated partial thromboplastin time (aPTT) >  seconds above the upper limit of normal for age, within  week prior to enrollment.
Screening laboratory values (serum chemistry, hematology, prothrombin time [PT](international normalized ratio [INR])/activated partial thromboplastin time [APTT], and creatine phosphokinase [CPK]) obtained up to  days prior to administration of first vaccine injection on day  within institutional normal range or judged to be not clinically significant by principal investigator (PI) and medical monitor
Prothrombin time (PT)/international normalized ratio (INR) and partial thromboplastin time (PTT) (activated partial thromboplastin time [aPTT]) =< . x upper limit of normal
International normalized ratio (INR) and activated thromboplastin time within normal institutional limits
